Emerging data from the phase 3 FLAURA trial, which enrolled untreated patients with EGFR‐mutant NSCLC who then received osimertinib versus a reversible EGFR‐TKI (erlotinib or gefitinib), showed a better median PFS in the patients treated with osimertinib (18.9 months vs. 10.2 months; HR 0.46).9 This evidence concerns the gene EGFR and non-small cell lung carcinoma.